Pharmacologic View of Tardive Dyskinesia

CE / CME

A Pharmacologic View of Tardive Dyskinesia: Pathology and Treatment

Nurses: 1.00 Nursing contact hour, including 1.00 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

Psychologists: 1.00 APA CE Credit

Social Workers: 1.00 ASWB ACE CE Credit

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Released: December 27, 2024

Expiration: December 26, 2025

Greg W. Mattingly
Greg W. Mattingly, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Of the following risk factors for developing TD, which is of particular relevance in older patients?

2.

Which of the following must be discontinued when using a VMAT2 inhibitor to treat TD?

3.

Which statement is true as supported by published data on VMAT2 inhibitors specific to older adults with TD?